BRK.B vs NBIX · rev $371.44B vs P/E 45, rev $1.77B
BRK.B (BRK.B) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
BRK.B (BRK.B) common stock. It is led by Warren Buffett.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported BRK.B revenue for 2025-12-31 was $371.44B. Net income was $66.97B. Revenue was up 616.8% from 2015-12-31 to 2025-12-31. BRK.B currently screens at market cap $0.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
BRK.B currently screens at market cap $0. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the BRK.B and NBIX stock pages for the full models.
Not investment advice.